These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 35764018)
1. Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers. Shi Y; Li Y; Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Lv C; Han S; Yu Y; Xu F; Tian Y Int Immunopharmacol; 2022 Sep; 110():108968. PubMed ID: 35764018 [TBL] [Abstract][Full Text] [Related]
2. The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. Melaiu O; Vanni G; Portarena I; Pistolese CA; Anemona L; Pomella S; Bei R; Buonomo OC; Roselli M; Mauriello A; Barillari G Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834641 [TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B Front Immunol; 2020; 11():1956. PubMed ID: 32983126 [TBL] [Abstract][Full Text] [Related]
4. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Lee WS; Yang H; Chon HJ; Kim C Exp Mol Med; 2020 Sep; 52(9):1475-1485. PubMed ID: 32913278 [TBL] [Abstract][Full Text] [Related]
5. Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy. Li S; Zhang Q; Hong Y Technol Cancer Res Treat; 2020; 19():1533033820980116. PubMed ID: 33287656 [TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment. Xue L; Gao X; Zhang H; Tang J; Wang Q; Li F; Li X; Yu X; Lu Z; Huang Y; Tang R; Yang W BMC Cancer; 2021 Oct; 21(1):1134. PubMed ID: 34686154 [TBL] [Abstract][Full Text] [Related]
7. Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications. Zhou S; Zhang H Anticancer Agents Med Chem; 2020; 20(7):768-776. PubMed ID: 32031076 [TBL] [Abstract][Full Text] [Related]
8. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade. Zheng W; Qian C; Tang Y; Yang C; Zhou Y; Shen P; Chen W; Yu S; Wei Z; Wang A; Lu Y; Zhao Y Front Immunol; 2022; 13():1035323. PubMed ID: 36439137 [TBL] [Abstract][Full Text] [Related]
9. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Xing R; Gao J; Cui Q; Wang Q Front Immunol; 2021; 12():783236. PubMed ID: 34899747 [TBL] [Abstract][Full Text] [Related]
10. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. Missiaen R; Mazzone M; Bergers G Semin Cancer Biol; 2018 Oct; 52(Pt 2):107-116. PubMed ID: 29935312 [TBL] [Abstract][Full Text] [Related]
11. Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy. Qian C; Liu C; Liu W; Zhou R; Zhao L Front Immunol; 2023; 14():1291530. PubMed ID: 38193080 [TBL] [Abstract][Full Text] [Related]
12. Combining microenvironment normalization strategies to improve cancer immunotherapy. Mpekris F; Voutouri C; Baish JW; Duda DG; Munn LL; Stylianopoulos T; Jain RK Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3728-3737. PubMed ID: 32015113 [TBL] [Abstract][Full Text] [Related]
13. Angiogenic inhibitor pre-administration improves the therapeutic effects of immunotherapy. Sato M; Maishi N; Hida Y; Yanagawa-Matsuda A; Alam MT; Sakakibara-Konishi J; Nam JM; Onodera Y; Konno S; Hida K Cancer Med; 2023 Apr; 12(8):9760-9773. PubMed ID: 36808261 [TBL] [Abstract][Full Text] [Related]
14. The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer. Ren S; Xiong X; You H; Shen J; Zhou P Front Immunol; 2021; 12():689132. PubMed ID: 34149730 [TBL] [Abstract][Full Text] [Related]
16. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer. Georganaki M; van Hooren L; Dimberg A Front Immunol; 2018; 9():3081. PubMed ID: 30627131 [TBL] [Abstract][Full Text] [Related]
17. USP7 inhibitors suppress tumour neoangiogenesis and promote synergy with immune checkpoint inhibitors by downregulating fibroblast VEGF. Jurisic A; Sung PJ; Wappett M; Daubriac J; Lobb IT; Kung WW; Crawford N; Page N; Cassidy E; Feutren-Burton S; Rountree JSS; Helm MD; O'Dowd CR; Kennedy RD; Gavory G; Cranston AN; Longley DB; Jacq X; Harrison T Clin Transl Med; 2024 Apr; 14(4):e1648. PubMed ID: 38602256 [TBL] [Abstract][Full Text] [Related]
18. [Immune therapy and tumor angiogenesis]. Takakura N Rinsho Ketsueki; 2020; 61(9):1440-1445. PubMed ID: 33162547 [TBL] [Abstract][Full Text] [Related]
19. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Oladejo M; Paulishak W; Wood L Semin Cancer Biol; 2023 Jan; 88():81-95. PubMed ID: 36526110 [TBL] [Abstract][Full Text] [Related]
20. Angiogenesis as a hallmark of solid tumors - clinical perspectives. Majidpoor J; Mortezaee K Cell Oncol (Dordr); 2021 Aug; 44(4):715-737. PubMed ID: 33835425 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]